Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Adverum Biotechnologies to Present at Upcoming Investor Conferences
February 27, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
November 04, 2022 12:08 ET
|
Adverum Biotechnologies, Inc.
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in...
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
October 27, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
September 30, 2022 16:45 ET
|
Adverum Biotechnologies, Inc.
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision...
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
September 23, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
September 23, 2022 08:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
September 14, 2022 08:00 ET
|
Adverum Biotechnologies, Inc.
- LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF...
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...